EASL Studio Podcast: Resmetirom: First approved drug for MASH, for whom and for how long?

This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.FacultyAleksander Krag (Moderator)Naim Alkhouri (Faculty)Sven Francque (Faculty)Amalia Gastaldelli (Faculty)Related episodesSeason 5 , Episode 2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio from EASL Congress 2023: Steatotic liver disease global consensus to change nomenclatureSeason 4, Episode 23: The Conundrum of NASH: The Growing Global Disease Burden with Low Disease AwarenessSeason 4, Episode 22: JHEP Live: New and promising drugs for NASH on the horizonAll EASL Studio Podcasts are available on EASL Campus.